The results from the DESTINY-Breast04 trial proved the efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-low breast cancers, where heavily pretreated advanced HER2-low breast cancer patients achieved significantly improved survival compared with chemotherapy-treated patients8. Here, ERBB2 is linked to breast cancer.